Please login to the form below

Not currently logged in
Email:
Password:

CINV

This page shows the latest CINV news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

Relypsa. USA. rolapitant. Varubi. chemotherapy-induced nausea and vomiting (CINV). neurokinin-1 receptor antagonist.

Latest news

  • Merck plans expanded filing for Emend this year Merck plans expanded filing for Emend this year

    Merck &Co's nausea and vomiting therapy Emend is effective in preventing chemotherapy-induced nausea and vomiting (CINV) even when given as a single dose, says a new study. ... Generics aside, competition is building in the CINV sector. Last October the

  • GSK files NDA in the US

    FDA). The drug performed well during trials, with results showing that it significantly reduced the number of patients who experienced CINV. ... The company said that 40 to 50 per cent of patients still succumb to breakthrough CINV despite being on

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics